Augmenix completes Series D
Augmenix has closed a $10.8 million Series D fundraising. Participants in this round of financing included a new investor, Excelestar Ventures. Existing investors CHV II, Catalyst Health Ventures and Sparta Group also participated. Augmenix is based in Waltham, MA and is focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology.
24 July 2014•2 mins read
